VivoSeq
Oncology

Uterine Leiomyosarcoma

17

Pipeline Programs↗

4

Active Trials↗

12

Companies Involved↗

Uterine Leiomyosarcoma is an emerging landscape with 17 programs across 12 companies. The most active players are Bristol-Myers Squibb, Novartis, Mario Negri Institute for Pharmacological Research. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

6/100

Mech. Concentration

15/100

Completion Rate

56/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2Novartis logo

Novartis

2 programs

Phase 2Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2A

Avyxa

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

74%

Small molecule

14 of 19 classified programs — the dominant modality here.

26%ALL OTHERSMonoclonal antibody316%Protein / enzyme211%

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 100% of 19 pipeline programs.

Analysis

Trial Status

13

clinical trials

Completed5 · 38%
Terminated2 · 15%
Active, not recruiting2 · 15%
Recruiting2 · 15%
Withdrawn1 · 8%
Suspended1 · 8%

Clinical Trials

Trial Activity

13 trials

Letrozole in Uterine Leiomyosarcoma
Recruiting·GGOG Foundation·Phase 2·NCT05649956·40 enrolled
Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
Recruiting·UUNICANCER·Phase 2·NCT06524583·198 enrolled
A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03880019·23 enrolled
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
Active, not recruiting·National Cancer Institute (NCI)·Phase 2/3·NCT05432791·73 enrolled
Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma
Completed·GGynecologic Oncology Group·Phase 2·NCT00101127
Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT02428192·20 enrolled
Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma
Completed·Mario Negri Institute for Pharmacological Research logoMario Negri Institute for Pharmacological Research·Phase 2·NCT02249702·168 enrolled
Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
Completed·—·Phase 2·NCT00856050·27 enrolled
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT00282087·47 enrolled
Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in Uterine Leiomyosarcoma
Suspended·MM.D. Anderson Cancer Center·Phase 2·NCT07076186·48 enrolled
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Terminated·GGynecologic Oncology Group·Phase 3·NCT01533207·38 enrolled
Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00414076·9 enrolled
Pazopanib for Treating Uterine Leiomyosarcoma
Withdrawn·GGynecologic Oncology Group·Phase 2·NCT02378142

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)